Skip to main content

Table 1 Characteristics of the study populations in the clinical studies enrolled in the meta-analysis

From: Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study

Name of the study Type of DM Type of intervention Injected cells’ count Route of delivery Number of patientsN (Males/Females) Mean age (year) Mean duration of DM Total follow-up period (year) Country Reference
Hu et al., 2013 T1DM WJ-MSCs (Allogenic) 1.5–3.2 × 107 IV – Parenteral solution
Twice, 4 weeks interval
SC group: 15 (9/6)
Control group: 14 (8/6)
17.6 ± 8.7
18.2 ± 7.9
Newly onset - not more than 6 months 2 China [35]
Hu et al., 2016 T2DM WJ-MSCs (Allogenic) 1 × 106/kg IV – Parenteral solution
Twice, 4 weeks interval
SC group: 31 (17/14)
Control group: 30 (16/14)
52.4 ± 4.9
53.2 ± 8.2
8.9 ± 5.7 year
8.3 ± 6.07 year
3 China [36]
Liu et al., 2014 T2DM WJ-MSCs (Allogenic) 1 × 106/kg 1 IV and 1 IPA endovascular injection, 5 days interval SC group: 22 (15/7) 52.9 ± 10.5 8.7 ± 4.3 year 1 China [37]
Guan et al., 2015 T2DM WJ-MSCs (Allogenic) 1 × 106/kg IV infusion
Twice, 2 weeks interval
SC group: 6 (6/0) 40.5 ± 3.76 3.6 ± 1.9 year 2 China [38]
Cai et al., 2016 T1DM WJ-MSCs
(Allogenic) plus BM-MNCs (Autologous)
1.1 × 106/kg
WJ-MSCs plus
106.8 × 106/kg BM-MNCs
IPA (Once) SC group: 21 (9/12)
Control group: 21 (11/10)
18.3 ± 5.2
20.4 ± 3.7
9.2 ± 4.8 year
7 ± 3.3 year
1 USA [39]
Chen et al., 2016 (Article Chinese – English Abstract) T2DM WJ-MSCs (Allogenic) plus Liraglutide 1 × 106 cells/kg IPA infusion on the first day followed by IV infusion on the 8th, 15th and 22nd day SC group: 6 (NA)
Control group: 6 (NA)
NA Not more than 10 years 6 months China [40]
Haller et al., 2013 T1DM UCB (Autologous) plus vitamin D + DHA 1.1 × 107 cells/kg IV (Once) SC group: 10 (8/2)
Control group: 5 (3/2)
6–7 Newly diagnosed 1 USA [41]
Giannopoulou et al., 2013 T1DM UCB (Autologous) 3.89 × 107 cells/kg IV (Once) SC group: 7 (5/2)
Control group: 10 (4/6)
3.3 ± 1.3
6.9 ± 2.3
Newly diagnosed 1 Germany [42]
Haller et al., 2011 T1DM UCB (Autologous) 1.88 × 107 cells/kg IV (Once) SC group: 24 (10/14) 5.1 ± 2.8 0.32 ± 0.26 years 2 USA [43]
Haller et al., 2009 T1DM UCB (Autologous) 1.5 × 107 cells/kg IV (Once) SC group: 15 (8/7) 5.2 ± 3.4 6 months 1 USA [44]
Tong et al., 2013 T2DM UCB (Allogenic) 2.88 × 106 cells/kg IPA (Once) SC group: 3 (3/0) 40.7 ± 5.5 6.6 ± 5.6 year 6 months China [45]
  1. Abbreviations: WJ-MSCs Wharton’s jelly mesenchymal stem cells, UCB umbilical cord blood, BM-MNCs bone marrow-mononuclear cells, T1DM type 1 diabetes mellitus, T2DM type 1 diabetes mellitus, IV intravenous, IPA intra-pancreatic artery, and DHA docosahexaenoic acid